E-Eye - IPL dry eye treatment - NOW AVAILABLE FOR $25,900 + GST

Ask for a demonstration today. Demonstration Enquiry Shop for Accessories


E-Eye is the first medical device specifically designed and certified to prevent and treat dry eye using IRPL technology. Marketed in Australia and New Zealand since 2014, it has become the reference in dry eye management offering long lasting relief to patients for up to 29 months. 

The reference in the treatment of dry eye. Over 200 practices equipped with E-Eye in Australia and New Zealand. Available in 50 countries worldwide.

The most clinically documented IPL device in the market.

For clinically studies, click here.

Key Features

- Treat Meibomian Gland Dysfunction (MGD).
- Proven efficiency on mild, medium and severe dry eye.
- Stimulates the parasympathetic nerve to unblock the Meibomian Glands and improve the lipid quality.
- Fast and easy to operate by you and your staff.
- No. 1 dry eye solution.

Scientifically Proven Effectiveness

Quantified and cumulative efficiency

All the studies conducted on the E-Eye IPL device showed improvement in the quality of meibum but also on the compression of the Meibomian Glands. This improvement will last: About a week after the initial treatment. Two to three weeks after the second. Between 6 months to 3 years after the third session. The effect is cumulative.

Figure: Total symptom scores.

Notes: The total score of the 10 single symptoms were defined as the total symptom scores. (Dryness, Foreign body sensation, Itching, Burning, Visual Fatigue, Blurred Vision, Sensitivity to light, Watering, Secretion disturbance, Pain). *Compared to the baseline, the total symptom score significantly decreased at the time of D15, D45 and D75 (P<0.01). **Between the visits of D15 and D45, the total score continuously decreased (P<0.01), while between the visits of D45 and D75, no significant difference was observed (P=0.85).

An instant improvement

The stimulation leads to the Meibomian glands returning to their normal function in a very short time (a couple of hours) following the treatment.

In the long run

The treatment effects last 6 months to 3 years after the 3rd to 4th sessions. In 60% of cases, effects persist beyond 3 years after the treatment. According to the Oxford scheme (0,I, II, III, IV), patients with lower grade (1 and 2) are "easy” candidates that go down from 1 to 2 grades after the first 3 sessions.

Scientifically proven efficiency by 4 clinical studies

1 - Clinical trial in France, 2012


Dr Christian Malbrel, Ophthalmologist in Reims, France, undertook a clinical study in 2012 on 150 patients with MGD.


Results show 90% satisfaction rate after a serie of 3 treatments on day 1, 15 and 45.

2 - Clinical trial in New Zealand, 2014


Associate Professor Jennifer P. Craig from the Ocular Surface Laboratory within The University of Auckland’s Department of Ophthalmology, has published results of a prospective, double-masked clinical study using E-Eye technology for the treatment of MGD. This study has been published in the Association for Research and Vision in Ophthalmology’s (ARVO’s) journal of Investigative Ophthalmology & Visual Science.


Here are the results 45 days after 3 treatments:
  • Significant improvement in the Non-Invasive Tear Break Up Time (NIBUT) in the treated eye but not in the control one.
  • Significant improvement of the tear Lipid Layer Grade (LLG) measured with a TearScope.
  • 86% of participants noted reduced symptoms in the treated eye (SPEED score).


Figure: Non invasive tear break-up time of the treated and control improved from BL, with only one eye treated, bodes well for eye at each of the four visits. Non invasive tear break-up time was higher at D45 relative to BL in the treated eye (P < 0.001), but not in the control eye (P¼ 0.56). Additionally, NIBUT was significantly higher in the treated eye compared with the control eye at D45 (P < 0.001). *Significant difference between groups at P < 0.005. Error bars denote SEM.

Read more

3 - Clinical trial in China, Third Hospital of Pekin University, 2014


Evaluation of the safety and affectiveness of the Controlled Discharged Xenon Flash Lamp (IRPL) device in the treatment of Meibomian Gland Dysfunction caused dry eye.


Using Controlled Discharge Xenon Flash Lamp device treatment (energy level 13.0J/cm2), the dry eye symptoms were significantly relieved in patients who suffered from Meibomian Gland Dysfunction caused dry eye. The morphology of the palebral margin, the meibomian gland opening obstruction and the meibomian gland quantity were also improved. The difference between prior and post treatment was statistically significant. In addition, the Controlled Discharge Xenon Flash Lamp device therapy could improve the tear film quality, and prolonged the tear break up time. Following 4 consecutive treatments, the improvement to the dry eye symptom and the sign of the ocular tissues could be well maintained. Overall, this study had demonstrated that the Controlled Discharge Xenon Flash Lamp device treatment is safe and effective in the treatment of dry eye caused by Meibomian Gland Dysfunction.

Read more

4 - Clinical trial in France, 2012 - 2015


Dr Christian Malbrel run a second clinical study in France on 55 patients who have been treated early 2012 with a surveillance over 36 months. Each patient received on average three E-Eye sessions.


The clinical study reveals that 62% of the patients didn’t experience any recurrence after the initial treatment during this period. 38% of them had to complete an additional session 7.5 months after the initial treatment. The average gap of surveillance without having to give another treatment was 29.3 months.

Treatment Protocol

The eye care specialist adjusts the goggles on the patient’s eyes and applies hydrogel on the skin. A series of three to five gentle flashes are then applied under the lower eyelid. A session only takes a few minutes and no needles or injections are required.

The results are experienced a immediately after the treatment and the effect is cumulative:
- First session (Day 1): around one week relief
- Second session (Day 15): around two weeks relief
- Third session (Day 45): up to 18 months relief

A total of three sessions are recommended for optimum results. The third treatment being the trigger for long lasting efficiency. Additional sessions can be undertaken depending on patient needs.



Product name



E-SWIN (France)

Dimensions (Length x Width x Height)

Max 740 x 460 x 610 mm


Max 11kg

Noise level

Max 55 dBA


100 – 240 VAC

Max power consumption

540 VA


50/60 Hz

Usage temperature

+5°C - +25°C

Authorised humidity (without condensation)

30 – 93 %

Storage temperature

-5°C - +65°C

Storage authorised humidity (without condensation)

30 - 93 %



Download Brochure

Download dry eye protocol

E-Eye on A Current Affair


How to use the E-Eye


How does E-Eye work